Remediation activities at non-GMP compliant site ‘progressing well’, says Recipharm

By Flora Southey contact

- Last updated on GMT

(Image: Getty/steved_np3)
(Image: Getty/steved_np3)
An MHRA audit of Recipharm’s facility in Ashton-under-Lyne has revealed the CDMO was deficient in certain manufacturing procedures for potent products.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) routinely inspected the Swedish contract development and manufacturing organisation (CDMO)’s facility on August 24, 2018.

According to the agency, inspectors observed that the facility’s potent drug production area lacked appropriate measures to prevent and detect cross-contamination.

The MHRA considered the lack of such measures“presented a risk that cross-contamination between products could occur and would not be detected”.

According to Recipharm, the agency has since made a formal decision regarding on-site production for certain drug products: “On 24th September 2018, the MHRA formally restricted the manufacturing licence for a limited number of products,” ​a company spokesperson told us.

“We continue to work with the authorities and customers to implement appropriate remediation activities which is progressing well,” ​the spokesperson added.

Recipharm appeared in headlines earlier this week, having reversed its decision​ to close a sachet and stick pack-filling facility in Höganäs, Sweden.

“The decision to stay in Höganäs is a consequence of the increased demand for the technology and capacity we can offer,” ​wrote CEO Thomas Eldered in a statement​.

“This has been somewhat unexpected, but we are of course pleased to see new customers entering in Höganäs and that, by this, we are also able to continue the services to existing customers,” ​he added.

Related news

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us


View more